The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.05.06.21256738: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: All patients provided informed consent to participate in the study, which was approved by the ethics committee of TMCH (approval number: 2020-071).
IRB: All patients provided informed consent to participate in the study, which was approved by the ethics committee of TMCH (approval number: 2020-071).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The N2 primer/probe set (Nihon Gene Research Laboratories, Miyagi, Japan) was employed for reference RT-PCR as suggested by the “Manual for the Detection of Pathogen 2019-nCoV Ver. 2.9.1” issued by the National … SciScore for 10.1101/2021.05.06.21256738: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: All patients provided informed consent to participate in the study, which was approved by the ethics committee of TMCH (approval number: 2020-071).
IRB: All patients provided informed consent to participate in the study, which was approved by the ethics committee of TMCH (approval number: 2020-071).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The N2 primer/probe set (Nihon Gene Research Laboratories, Miyagi, Japan) was employed for reference RT-PCR as suggested by the “Manual for the Detection of Pathogen 2019-nCoV Ver. 2.9.1” issued by the National Institute of Infectious Diseases of Japan [9]. Nihon Gene Research Laboratoriessuggested: (University of Southern California; Los Angeles; USA, RRID:SCR_008093)Limits of detection of QuickChaser® Auto SARS-CoV-2 and four commercially available rapid antigen tests: We compared the limit of detection (LOD) of QuickChaser® Auto SARS-CoV-2 with those of four commercially available rapid antigen tests (Espline® SARS-CoV-2, Fujirebio, Tokyo, Japan; QuickNavi™-COVID19 Ag, Denka, Tokyo Japan; Panbio™ COVID-19 Ag Rapid Test Device, Abbott Diagnostics, Illinois, USA; SARS-CoV-2 Rapid Antigen Test, Roche Diagnostics, Rotkreuz, Switzerland). Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are several limitations regarding this study. First, reference real-time RT-PCR used frozen samples. While samples were stored at -80 °C, their viral load may have decreased during storage process. Second, we did not investigate whether mutations in SARS-COV-2 affected the diagnostic performance. Third, we did not evaluate saliva or anterior nasal cavity samples. Saliva collection and anterior nasal swabs cause less pain and coughing than nasopharyngeal swabs [18]. Future studies should compare the diagnostic performance of samples obtained using each of these methods. In conclusion, Quick Chaser® Auto SARS-CoV-2 showed satisfactory diagnostic performance of symptomatic patients. The sensitivity was especially high in samples of Ct <30, indicating that the test can accurately detect highly infectious patients.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
